Cancer vaccines as a therapeutic strategy

Expert Review of Vaccines

Volumn 3, Issue 6, 2004, Pages 665-668

  Dalgleish, Angus G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antigen presenting cells; Cancer vaccine; Tumor

Indexed keywords

BCG VACCINE; CANCER VACCINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; MEGAVAX; QS 21; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNIZATION; MELANOMA; PRIORITY JOURNAL; REVIEW; TH1 CELL;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 9644276901     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.6.665     Document Type: Review

References (9)

1. Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG. Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br. J. Cancer 82(5), 1009-1012 (2000).
2. Livingston PO, Wong GY, Adluri S et al. Improved survival in Stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12(5), 1036-1044 (1994).
3. O'Brien ME, Saini A, Smith IE et al. A randomized Phase II study of SRL172 (Mycobacterium vaccae combined with chemotherapy in patients with advanced inoperable nonsmall cell lung cancer and mesothelioma. Br. J. Cancer 83(7), 853-857 (2000).
4. Assersohn L, Souberbielle BE, O'Brien ME et al. A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. Clin. Oncol. (R. Coll. Radiol) 14(1), 23-27 (2002).
5. Maraveyas A, Baban B, Kennard D et al. Possible improved survival of patients with Stage IV AJCC melanoma receiving SRL172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann. Oncol. 10, 817-824 (1999).
6. O'Brien ME, Anderson H, Kaukel E et al., SR-ON-12 Study Group. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced nonsmall cell lung cancer: Phase III results. Ann. Oncol. 15(6), 906-914 (2004).
7. Palena C, Zhu M, Schlom J, Tsang KY. Human B-cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells. Blood 104(1), 192-199 (2004).
8. Tsang KY, Palena C, Gulley J, Arlen P, Schlom J. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC1. Clin. Cancer Res. 10(6), 2139-2149 (2004).
9. Dredge K, Marriott JB, Todryk SM et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J. Immunol. 168(10), 4914-4919 (2002).